Assertio (ASRT) Competitors

Assertio (NASDAQ:ASRT) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Do analysts rate ASRT or AMLX?

Assertio currently has a consensus price target of $3.25, indicating a potential upside of 242.11%. Amylyx Pharmaceuticals has a consensus price target of $11.43, indicating a potential upside of 118.52%. Given Assertio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Assertio is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amylyx Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.60

Does the media favor ASRT or AMLX?

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Assertio. MarketBeat recorded 10 mentions for Amylyx Pharmaceuticals and 6 mentions for Assertio. Amylyx Pharmaceuticals' average media sentiment score of 0.90 beat Assertio's score of 0.75 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer ASRT or AMLX?

Assertio received 76 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. However, 65.31% of users gave Amylyx Pharmaceuticals an outperform vote while only 59.67% of users gave Assertio an outperform vote.

Company	Underperform	Outperform
Assertio	Outperform Votes 108 59.67%	Underperform Votes 73 40.33%
Amylyx Pharmaceuticals	Outperform Votes 32 65.31%	Underperform Votes 17 34.69%

Is ASRT or AMLX more profitable?

Amylyx Pharmaceuticals has a net margin of -17.86% compared to Assertio's net margin of -54.46%. Assertio's return on equity of 3.79% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-54.46%	3.79%	1.81%
Amylyx Pharmaceuticals	-17.86%	-36.97%	-29.61%

Which has more volatility and risk, ASRT or AMLX?

Assertio has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.7, suggesting that its stock price is 170% less volatile than the S&P 500.

Which has higher valuation and earnings, ASRT or AMLX?

Amylyx Pharmaceuticals has higher revenue and earnings than Assertio. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$152.07M	0.60	-$331.94M	-$0.73	-1.30
Amylyx Pharmaceuticals	$196.49M	1.82	$49.27M	-$3.82	-1.37

Do institutionals and insiders believe in ASRT or AMLX?

49.0% of Assertio shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 3.2% of Assertio shares are held by company insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Amylyx Pharmaceuticals beats Assertio on 11 of the 19 factors compared between the two stocks.